Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Industry is anticipated to hit US$ 5.5 Billion by 2030, as indicated by FMI Analysis

Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Industry

The global Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Industry has valued at US$ 3.9 billion in 2022 and is anticipated to grow to US$ 5.5 billion by 2030, with sales revenue set to experience a CAGR of 4.3% during the forecast period. based on a recent market investigation by Future Market Insights (FMI).

Sepsis, toxic shock syndrome, bacteremia, osteomyelitis, endocarditis, meningitis, and pneumonia are only a few of the severe conditions caused by Staphylococcus aureus germs. Certain problems are treated with antibiotics.

Staphylococcus aureus strains that have developed resistance to a variety of antibiotics are referred to as “methicillin-resistant staphylococcus aureus (MRSA) treatment industry”. This resistance will likely be one of the major factors affecting the industry in the near future, hence extensive research should be done to create new medications.

Request A Report Sample To Gain Comprehensive Insights! https://www.futuremarketinsights.com/reports/sample/rep-gb-10406

According to FMI’s latest study, the rising incidences of MRSA all over the world are likely to create demand for safe and efficient drugs during the forecast period.

Key Takeaways of Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Industry Study: 

• In terms of drug class, glycopeptides (vancomycin) and oxazolidinones (linezolid) are collectively expected to account for over 75% of revenue share in the MRSA treatment market owing to preference of both antibiotic classes as a first-line treatment against MRSA infections and used in more than 80% of MRSA cases treatment.

• By route of administration, intravenous (IV) route of administration remains the recommended option. Drugs that can be administered through IV are likely to gain more than one-half of market share in the MRSA treatment market during the forecast period.
• By indication, skin and soft tissue infections (SSTIs) are leading the market and expected to gain more than 40% of revenue share followed by the pneumonia over the forecast period.
• Incidence of healthcare acquired MRSA is higher than community acquired MRSA, and FMI opines status-quo to remain unchanged during the assessment period
• North America is the highest revenue generating market by region due to high incidence of MRSA infections
• Asia Pacific is expected to witness high demand for MRSA testing systems due to high incidences of MRSA infection herein. For example – Journal of Family Medicine and Primary Care, in 2021, stated that occurrence of MRSA among kids aged 5 to 15 is between 16 and 52%. India alone accounts for 4-19% of these infections.

Connect With Our Analyst To Address Any Inquiries You May Have! https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-10406

Government and Pharma Industry Focus on Working in Unison to Develop Advanced Treat:

As per University of Melbourne’s researchers, “Teixobactin” responds positively against MRSA. These results are likely to pave the way for development of antibacterial drugs to treat multi-drug resistant Gram-positive infections with thick cell wall. This will open wider doors for MRSA treatment market all over Australia and the other countries in Asia-Pacific. Teixobactin is already known for destroying Mycobacterium tuberculosis.

Key Companies Profiled:

• Pfizer, Inc.
• Allergan Plc.
• Johnsons & Johnson
• Colgate-Palmolive Company
• The Procter & Gamble
• Merck & Co., Inc.
• Baxter Healthcare Corporation
• Fresenius Kabi LLC
• Sandoz Inc.
• Teva Pharmaceutical Industries ltd.
• Mylan N. V.
• Dr.Reddy’s Laboratories Inc.,
• Cumberland Pharmaceuticals Inc.

Unlocking the Power of Personalization: Embrace Customization in Our Latest Report! https://www.futuremarketinsights.com/customization-available/rep-gb-10406

Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Industry By Category:

By Drug Class:

• Glycopeptides
  • Vancomycin
• Oxazolidinones
  • Linezolid
• Lipopeptides
  • Daptomycin
• Antiseptics
  • Chlorhexidine
  • Cetylpyridinium Chloride
  • Hydrogen Peroxide
  • Phenols
• Lipoglycopeptides
  • Dalbavancin
  • Telavancin
  • Oritavancin
• Glycylcycline
  • Tigecycline
• Streptogramins
  • Quinupristin
  • Dalfopristin
• Naturals/Herbals
• Tetracycline
  • Doxycycline
  • Minocycline
• Lincomycin
  • Clindamycin
• Others

By Indication:

• Skin and Soft Tissue Infections (SSTIs)
• Pneumonia
• Bloodstream Infections
• Surgical and Medical Infections
• Others

By Route of Administration:

• Intravenous
• Oral
• Topical
• Nasal
• Cutaneous
• Intramuscular

By Type of MSRA:

• Healthcare Acquired MRSA
• Community Acquired MRSA
• Hospital Acquired MRSA

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube